Alnylam Pharma (ALNY) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents	271.08M
Marketable securities	571.99M
Collaboration receivables	9.51M
Income taxes receivable
Prepaid expenses and other current assets	22.15M
Total current assets	888.07M
Marketable securities
Property and equipment, net	55.39M
Investment in joint venture (Regulus Therapeutics Inc.)
Intangible assets, net
Total assets	1.38B
Accounts payable	12.82M
Accrued expenses	37.55M
Deferred rent	1.32M
Deferred revenue	18.89M
Total current liabilities	70.58M
Deferred rent, net of current portion	6.52M
Deferred revenue, net of current portion	54.81M
Other long-term liabilities	1.78M
Total liabilities	283.68M
Commitments and contingencies (Notes 4, 5 and 6)	0
Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued and outstanding at June 30, 2011 and December 31,2010	0
Common stock, $0.01 par value, 125,000,000 shares authorized;42,653,915 shares issued and outstanding at June 30, 2011; 42,343,423 shares issued and outstanding at December 31, 2010	856K
Additional paid-in capital	2.57B
Accumulated other comprehensive (loss) income	-28.3M
Accumulated deficit	-1.44B
Total stockholders' equity	1.1B
Total liabilities and stockholders' equity	1.38B

Entities mentioned with ALNY

View All Entities